Probi
348
SEK
0 %
PROB
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
0%
+41.46%
+33.85%
+39.2%
+71.43%
+70.59%
-9.61%
+45.91%
+3,144.05%
Probi is a biotechnology company. The company is particularly focused on the research and development of probiotics, a bacterium that is found in the human intestinal system. The research areas within the company include the gastrointestinal, immune system, metabolic syndrome, and stress and recovery. The company's customers include larger corporate customers active in the food industry. The company was founded in 1991 and is headquartered in Lund.
Read moreMarket cap
3.97B SEK
Turnover
1.68M SEK
Revenue
627.69M
EBIT %
1.8 %
P/E
235.14
Dividend yield-%
0.37 %
Financial calendar
28/1
2025
Annual report '24
23/4
2025
Interim report Q1'25
6/5
2025
General meeting '24
ShowingAll content types
Uttalande från den oberoende budkommittén i Probi med anledning av Symrise offentliga uppköpserbjudande
Analysguiden: KOMMENTAR Probi: Största ägaren lägger bud
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools